VA places new ALS treatment option on national coverage list

30 November 2017

The US Department of Veterans Affairs (VA) has placed the first new Food and Drug Administration-approved treatment option for amyotrophic lateral sclerosis (ALS) in more than 20 years on its National Formulary for coverage.

The drug in question is Japanese drug major Mitsubishi Tanabe Pharma’s (TYO: 4508) Radicava (edaravone), which gained FDA approval in May and was launched in the USA in August this year.

The VANF put in place a national prior authorization process, making it possible for veterans with ALS, also known as Lou Gehrig’s disease, to access treatment within VA’s comprehensive healthcare system. Radicava is not a cure for ALS, but it has been shown to slow decline in the loss of physical function.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK